Johnson & Johnson Ends Global Sales of Cancer-Causing Baby Powder Amid Increased Scrutiny from Consumer Litigation, Science

Courts continue to scrutinize J&J's controversial bankruptcy ploy to avoid liability

Legal experts say the decision by Johnson & Johnson (NYSE: JNJ) to halt future sales and distribution of talc-based products worldwide, including its iconic Johnson's Baby Powder, points to mounting pressure on the company to resolve tens of thousands of legal claims brought by ovarian cancer and mesothelioma victims.

Numerous scientific studies spanning decades have established the carcinogenic effects of cosmetic talc, while U.S. and Canadian governmental regulators have called for enhanced testing techniques for products containing the mineral, particularly after independent testing by the U.S. Food & Drug Administration revealed asbestos in consumer samples of talc-based powders. Meanwhile, internal corporate documents presented in trials during the past several years have shown that J&J and its consultants knew of the dangers of the company's products and took steps to deny or otherwise cover up those findings to avoid legal liability.

"J&J has finally done the right thing. Throughout decades of selling talc-based products, the company knew talc could cause deadly cancers to unsuspecting women and men around the world," says Leigh O'Dell of the Beasley Allen Law Firm in Montgomery . "They stopped sales in North America more than two years ago and blamed that move on the litigation. The delay in taking this step is inexcusable. I can only hope J&J will now do the next right: take responsibility and adequately compensate the victims they have needlessly harmed."

The vast majority of the more than 38,000 cases filed by ovarian cancer victims against J&J were consolidated in multidistrict litigation in New Jersey federal court, and bellwether trials had been scheduled to begin last spring. Those proceedings were put on hold in late 2021 when the company chose to pursue a controversial "Texas Two-Step" bankruptcy.

That scheme involved creating a new corporate shell company to hold all talc-related liabilities before taking that entity into bankruptcy. If successful, the tactic would allow Johnson & Johnson to avoid paying cancer victims and protect a market capitalization of approximately a half-trillion dollars. Because of the bankruptcy, all trials in the MDL and others filed in state courts are currently suspended.

The two-step move has raised eyebrows in Congress, where representatives have begun discussing potential changes to the bankruptcy laws that would prevent this sort of consumer harm in future cases.

"The potential loss of a jury trial is not a mere by-product of the filing; the sole purpose of the bankruptcy is to remove tort claimants from the tort system and strip them of their rights against extraordinarily wealthy and highly solvent entities," wrote Erwin Chemerinsky , Dean of the University of California's Berkeley School of Law, in a brief filed with the bankruptcy court.

"The Debtor is a newly created shell, with no business to restructure, no operations to rehabilitate, and no customers or genuine employees to serve. In short, the Debtor has no reorganizational purpose," he noted in the brief, one of many filed by constitutional scholars raising concerns about the "Two-Step."

The propriety of the bankruptcy and accompanying halt to litigation imposed by the bankruptcy court will be reviewed by the U.S. Court of Appeals for the Third Circuit in a hearing Sept. 19 .

About Beasley Allen Law Firm

Headquartered in Montgomery, Ala. , Beasley Allen is comprised of more than 70 attorneys and 200 support staff. One of the largest Plaintiffs law firms in the country, Beasley Allen is a national leader in civil litigation, with verdicts and settlements in excess of $26 billion . Beasley Allen was one of only 12 firms in the nation named by Law360 to its Most Feared Plaintiffs Firms list in 2015, and the firm was included on the National Law Journal Midsize Law Firm Hot List and the NLJ Elite Trial Lawyers List in 2014. For more information about our firm, please visit our website at www.beasleyallen.com .

Media Contact:

Barry Pound
800-559-4534
Barry@androvett.com

Cision View original content: https://www.prnewswire.com/news-releases/johnson--johnson-ends-global-sales-of-cancer-causing-baby-powder-amid-increased-scrutiny-from-consumer-litigation-science-301605252.html

SOURCE Beasley Allen Law Firm

News Provided by PR Newswire via QuoteMedia

JNJ
The Conversation (0)
doctor with hands together, palms up below digital medical symbols

Innovations and Opportunities in European Healthcare Technologies

In recent years, European companies have emerged as trailblazers in healthcare technology, effectively changing the face of health and patient care. Through innovation, they're not only improving systems, processes and patient outcomes but also saving lives.

These advanced European technologies are often only distributed and implemented exclusively within the European Union. The good news is that it doesn't need to stay this way.

Bringing European healthcare technologies to the North American market can potentially improve healthcare in this part of the world, open up new market opportunities for investors and expose those companies to significant growth capital.

Keep reading...Show less
Johnson & Johnson to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Johnson & Johnson to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 44 th Annual Global Healthcare Conference on Tuesday, June 13 th , at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA. Biljana Naumovic, Worldwide Vice President, Oncology, and Peter Lebowitz, Global Therapeutic Head, Oncology, will represent the Company in a session scheduled at 4:20 p.m. (Eastern Time).

This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com .

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Johnson & Johnson and Kenvue Announce Pricing of Upsized Kenvue Inc. Initial Public Offering

Johnson & Johnson and Kenvue Announce Pricing of Upsized Kenvue Inc. Initial Public Offering

Johnson & Johnson (NYSE: JNJ) and Kenvue Inc. ("Kenvue"), a wholly owned subsidiary of Johnson & Johnson, today announced the pricing of Kenvue's upsized initial public offering ("IPO") of 172,812,560 shares of Kenvue's common stock at a price to the public of $22.00 per share. In addition, Kenvue has granted the underwriters a 30-day option to purchase up to an additional 25,921,884 shares of its common stock to cover over-allotments, if any. Kenvue's common stock has been approved for listing on the New York Stock Exchange under the symbol "KVUE" and is expected to begin trading on May 4, 2023. The IPO is expected to close on May 8, 2023, subject to the satisfaction or waiver of customary closing conditions.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Johnson & Johnson to Participate in the Bernstein 39th Annual Strategic Decisions Conference

Johnson & Johnson to Participate in the Bernstein 39th Annual Strategic Decisions Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein 39 th Annual Strategic Decisions Conference on Wednesday, May 31 st , at the New York Hilton Midtown in New York. Joaquin Duato, Chairman of the Board and Chief Executive Officer will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time).

This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com .

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Kaleido Collaborates with Janssen on Metabolic Therapies

Kaleido Biosciences (NADAQ:KLDO) announced a research collaboration with Janssen’s World Without Disease Accelerator, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE:JNJ).

As quoted in the press release:

Keep reading...Show less

Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

  • Initiated enrollment of the BACKBEAT global pivotal study evaluating AVIM therapy (also known as BackBeat Cardiac Neuromodulation Therapy) in hypertensive pacemaker patients in collaboration with Medtronic, plc (NYSE: MDT) in December 2023
  • Orchestra BioMed and Terumo remain actively engaged to update operational plans and financial arrangements for Virtue ® Sirolimus AngioInfusion TM Balloon ("SAB") development and commercialization for treatment of coronary and peripheral artery disease
  • Expected runway of cash and cash equivalents and marketable securities, including certain potential future proceeds sufficient into 2H 2026, beyond anticipated BACKBEAT top-line results readout

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2023 financial results and provided a fourth quarter business update.

"2023 was a year of strong momentum for Orchestra BioMed as we made significant progress on our cardiovascular pipeline with the achievement of key regulatory milestones and completion of our successful Nasdaq listing," commented David Hochman, chairman, chief executive officer and founder of Orchestra BioMed. "In December, we initiated the BACKBEAT global pivotal study evaluating our lead program, AVIM therapy, in hypertensive pacemaker patients working alongside our strategic partner Medtronic, the global market leader in cardiac pacing therapies. We see a substantial market opportunity for AVIM therapy in this patient population, as well as in other high-risk hypertension populations."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Medtronic announces FDA approval of newest-generation Evolut TAVR system for treatment of symptomatic severe aortic stenosis

The Evolutâ„¢ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

U.S. Patent Office rejects Axonics' latest challenge to Medtronic patents

Medtronic moves for patent infringement litigation to resume

Medtronic (NYSE:MDT), the global leader in healthcare technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed the validity of claims in two of its patents in an ongoing patent infringement lawsuit filed by Medtronic against Axonics over sacral neuromodulation (SNM) technologies. Cumulatively, the PTAB has now upheld the validity of five of the Medtronic patents at issue in this lawsuit.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company"), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2023. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.

2023 Highlights

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Glen Eagle Resources Inc.

(TheNewswire)

Glen Eagle Resources Inc.

Glen Eagle Resources Inc. ( TSX VENTURE: GER) ("Glen Eagle" or the "Company")  announces that the court has homologated the judgement, ordering the Company to pay Gem Yield Bahamas Limited a compensation of $1,875,895 dollars including interest and $90,000 in penalty

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2023 financial results on Thursday, March 21, 2024 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date : Thursday, March 21, 2024

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×